Apogee Therapeutics, Inc.
APGE
Ранг среди акций
#2366
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Цена акции
$135.07
Последняя синхронизация: 2026-09-04
Рыночная капитализация
$8.36B
Изменение (1 день)
0.00%
Изменение (1 год)
137.21%
Страна
US
Торговля Apogee Therapeutics, Inc. (APGE)
Категория
Healthcare
Коэффициент P/B для Apogee Therapeutics, Inc. (APGE)
Коэффициент P/B на October 2026 TTM: 8.53
Согласно последним финансовым отчетам и цене акций Apogee Therapeutics, Inc., текущий коэффициент P/B (TTM) составляет 8.53. В конце 2023 он составлял 3.73.
История P/B для Apogee Therapeutics, Inc. с 2022 по 2026
Коэффициент P/B в конце каждого года
| Год | P/B | Изменить |
|---|---|---|
| 2026 (TTM) | 8.53 | 144.42% |
| 2024 | 3.49 | -6.37% |
| 2023 | 3.73 | -50.80% |
| 2022 | 7.57 | 0.00% |
Коэффициент P/B для аналогичных компаний или конкурентов
| Компания | P/B | Разница P/B | Страна |
|---|---|---|---|
| 6.251 | -26.72% |
US
|
|
| 13.2547 | 55.39% |
US
|
|
| 4.208 | -50.67% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -27.52% |
NL
|
